ScholarIQanswers from OpenAlex

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment

PaperCitations, authors & open-access status

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment have?

ScholarIQcitation count

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment has 80 citations in the OpenAlex counts ScholarIQ stores.

When was Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment published?

ScholarIQyear

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment has 2020 year in the ScholarIQ index.

What is the open-access status of Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment?

ScholarIQoa status

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment has hybrid oa status in the ScholarIQ index.

What is the DOI of Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment?

ScholarIQdoi

The DOI for Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment is on the source record.

What is the PMID of Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment?

ScholarIQpmid

The PMID for Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment is on the source record.

What is the OpenAlex record for Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment?

ScholarIQopenalex

The OpenAlex for Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial